In a convergence of South Korean innovation and European distribution reach, Bio-Rad Laboratories and Gencurix have formalized an exclusive partnership to bring highly sensitive digital PCR oncology testing kits to clinical laboratories across Europe. The agreement reflects a broader movement in medicine toward precision diagnostics — where the ability to detect rare genetic mutations in a patient's blood or tissue can determine not just a diagnosis, but the entire course of treatment. At its heart, this is a story about closing the distance between scientific capability and the patients who n
Bio-Rad expands Gencurix partnership as exclusive European distributor of oncology PCR kits
Rare mutations become visible when DNA is split into thousands of tiny droplets
Mark
Why does it matter that Bio-Rad is specifically the exclusive distributor, rather than just one of several options?
Mimi
Exclusivity means Gencurix is betting entirely on Bio-Rad's network and reputation. It's a signal of confidence, but it also means European labs won't have competing suppliers to choose from—they'll go through Bio-Rad or not at all.
Mark
What's the practical difference between testing tissue samples and liquid biopsies for cancer mutations?
Mimi
Tissue biopsies require an invasive procedure—a biopsy needle or surgery. Liquid biopsies are just a blood draw. Both can reveal the same mutations, but liquid biopsies are faster, less risky, and can be repeated easily. Having both options means clinicians can choose based on what's already available or what the patient can tolerate.
Mark
Why does digital PCR's droplet approach matter so much for cancer detection?
Mimi
Cancer mutations often hide in a sea of normal DNA. Conventional PCR can miss them if they're rare. Digital PCR splits the sample into thousands of tiny droplets, so each one is amplified separately. That makes rare mutations visible—which is exactly what you need when you're hunting for tumor DNA in a blood sample.
Mark
Who benefits most from this partnership—the companies or the patients?
Mimi
Both, but differently. The companies expand their market and revenue. Patients benefit if their doctors actually use these tests to guide treatment. The real question is whether European labs will adopt them widely enough to change how cancer care actually happens.
Mark
What does "CE-marked" mean in practical terms?
Mimi
It means the kits have been validated and approved for clinical use in Europe. Without that mark, they couldn't be sold to diagnostic labs. It's regulatory clearance—proof the tests work as claimed.
Der Puls
- Cancer diagnostics in Europe face a persistent gap between cutting-edge mutation detection technology and what most clinical laboratories can actually access and deploy.
- Gencurix's Droplex kits — capable of identifying melanoma, colorectal, and lung cancer mutations in both tissue samples and liquid biopsies — represent a meaningful leap in sensitivity over conventional testing methods.
- Bio-Rad's existing QXDx digital PCR platform and established European commercial network give this partnership immediate infrastructure, reducing the friction of bringing a validated foreign technology to new markets.
- The two companies are not simply signing a distribution deal — they are committing to joint marketing and collaborative product development, signaling a longer-term strategic alignment.
- The trajectory points toward broader biomarker-guided cancer care across Europe, where physicians could increasingly rely on precise mutation data to select therapies and anticipate how patients will respond to treatment.
In a convergence of South Korean innovation and European distribution reach, Bio-Rad Laboratories and Gencurix have formalized an exclusive partnership to bring highly sensitive digital PCR oncology testing kits to clinical laboratories across Europe. The agreement reflects a broader movement in medicine toward precision diagnostics — where the ability to detect rare genetic mutations in a patient's blood or tissue can determine not just a diagnosis, but the entire course of treatment. At its heart, this is a story about closing the distance between scientific capability and the patients who need it most.
Bio-Rad Laboratories and South Korean oncology diagnostics firm Gencurix have signed an exclusive distribution agreement that will place Gencurix's Droplex digital PCR testing kits inside clinical laboratories across Europe. Bio-Rad becomes the sole European distributor of these CE-marked tools, which are engineered to detect cancer-related genetic mutations with exceptional sensitivity in both preserved tissue specimens and blood-based liquid biopsies.
The Droplex kits run on Bio-Rad's QXDx digital PCR platform and are designed to identify mutations linked to three major cancer types: melanoma, colorectal cancer, and non-small cell lung cancer. Their dual compatibility — working with both standard pathology lab specimens and circulating tumor DNA from blood — gives clinicians meaningful flexibility in how they test patients.
Digital PCR achieves its sensitivity by partitioning DNA into thousands of individual droplets before amplification, allowing it to detect rare mutations even when tumor DNA represents only a tiny fraction of a sample. In cancer diagnostics, where that precision can determine which therapy a patient receives, this capability carries real clinical weight.
For Gencurix, the deal validates its technology for broader European deployment and pairs it with Bio-Rad's deep ddPCR expertise and established commercial reach. For Bio-Rad, it adds a portfolio of ready-to-use oncology kits to its existing platform infrastructure. Both companies plan joint marketing and collaborative development as the partnership matures.
Leaders from both sides framed the agreement as a commitment to grounding treatment decisions in reliable biomarker data — a goal that, as precision oncology continues to expand, stands to benefit patients across Europe who currently lack access to this level of diagnostic precision.
Bio-Rad Laboratories and Gencurix, a South Korean oncology diagnostics company, have formalized an exclusive distribution agreement that will bring Gencurix's Droplex digital PCR testing kits to clinical laboratories across Europe. Under the deal, Bio-Rad becomes the sole distributor of these CE-marked diagnostic tools, which are designed to detect cancer-related genetic mutations with high sensitivity in tissue and blood samples.
The Droplex kits work on Bio-Rad's QXDx digital PCR platform and are built to identify mutations associated with three major cancer types: melanoma, colorectal cancer, and non-small cell lung cancer. The tests can analyze both formalin-fixed paraffin-embedded tissue samples—the standard preserved specimens stored in pathology labs—and liquid biopsies, which are blood-based tests that can detect circulating tumor DNA. This dual capability gives clinicians flexibility in how they approach patient testing.
The partnership expands an existing relationship between the two companies and represents a significant commercial step for Gencurix, whose technology has now been validated for broader European deployment. For Bio-Rad, the agreement strengthens its position in the precision oncology diagnostics space by adding a portfolio of ready-to-use testing kits to its existing digital PCR infrastructure. The companies plan to pursue joint marketing efforts and collaborative product development as part of the arrangement.
Steve Kulisch, who leads product management for Bio-Rad's Digital Biology Group, framed the deal as a way to deliver reliable molecular diagnostic tools to European laboratories while maintaining high standards of accuracy. He emphasized that the combination of Gencurix's Droplex kits and Bio-Rad's QXDx platform would enable physicians to base treatment decisions on solid biomarker data, ultimately improving how patients are cared for. Sang Rae Cho, Gencurix's CEO, called the partnership a validation of the company's technology and highlighted Bio-Rad's deep expertise in digital PCR and its established network across Europe as the reason for the choice.
Digital PCR technology, which partitions DNA samples into thousands of individual droplets before amplification, offers greater sensitivity than conventional PCR methods. This means it can detect rare mutations even when they represent a small fraction of the total DNA in a sample—a critical advantage in cancer diagnostics, where tumor DNA may be sparse among healthy cells. The Droplex kits leverage this sensitivity to provide clinicians with precise mutation information that can guide therapy selection and help predict treatment response.
The agreement signals growing momentum in precision oncology, where diagnostic accuracy directly influences which drugs patients receive and how well those drugs work. By expanding access to these tools across Europe, the partnership aims to make biomarker-guided cancer care more widely available to patients and physicians who currently may lack access to such testing.
Bemerkenswerte Zitate
This partnership will provide clinical laboratories with access to highly sensitive and reliable molecular tools, supporting compliance while ensuring the highest standards of diagnostic accuracy.— Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories
Bio-Rad's extensive European distribution capabilities and deep expertise in digital PCR technology make them the ideal partner to bring our oncology testing solutions to a broader market.— Sang Rae Cho, CEO, Gencurix
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical.net ↗
Health & Medicine